Using an in silico cohort of IFN-treated melanoma tissues, we validated a differentially expressed 9-gene core of DEGs, out of which four genes had a predictive power for efficacy: WFDC1, HSPB7, HSF1, and MT2A. This evidence concerns the gene HSPB7 and melanoma.